» Articles » PMID: 9867126

Enhanced Osteopontin Expression and Macrophage Infiltration in MRL-Fas(lpr) Mice with Lupus Nephritis

Overview
Journal Autoimmunity
Date 1998 Dec 29
PMID 9867126
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

MRL-Fas(lpr) mice spontaneously develop a chronic lupus-like renal disease, characterized by immune complex-mediated glomerulonephritis and abundant mononuclear cell infiltration in the interstitium. In the present study we have examined whether the macrophage chemoattractant osteopontin (Opn) could be important in the recruitment of macrophages in this murine model of autoimmune renal injury. We have examined the expression of Opn in the kidney of MRL-Fas(lpr) mice and have correlated Opn synthesis with the degree of macrophage infiltration. Immunofluorescence staining revealed prominent expression of Opn by proximal tubules in MRL-Fas(lpr) mice but not in MRL-++ control mice. Northern blot analysis demonstrated that steady-state transcript levels for Opn mRNA were also significantly increased in MRL-Fas(lpr) kidneys compared with control kidneys. Furthermore, in situ hybridization showed massive Opn mRNA transcripts in proximal tubules in MRL-Fas(lpr) mice but not in controls. The diffuse macrophage infiltration in the kidney of MRL-Fas(lpr) correlated with the enhanced Opn expression. Opn secretion in vitro by cultured renal tubular epithelial cells was upregulated by TNF-alpha and 1,25(OH)2-vitamin D3, whereas no regulation was observed in a control macrophage cell line. We conclude that the enhanced expression of the chemotactic molecule Opn by tubular cells is a prominent feature of murine lupus nephritis and might be promoted by the proinflammatory cytokine environment in MRL-Fas(lpr). The chronic upregulation of Opn could participate in the recruitment of monocytes in the kidney of MRL-Fas(lpr) mice, thereby contributing to the pathogenesis of autoimmune renal disease.

Citing Articles

Osteopontin in autoimmune disorders: current knowledge and future perspective.

Xu C, Wu Y, Liu N Inflammopharmacology. 2022; 30(2):385-396.

PMID: 35235108 DOI: 10.1007/s10787-022-00932-0.


Osteopontin binds ICOSL promoting tumor metastasis.

Raineri D, Dianzani C, Cappellano G, Maione F, Baldanzi G, Iacobucci I Commun Biol. 2020; 3(1):615.

PMID: 33106594 PMC: 7588454. DOI: 10.1038/s42003-020-01333-1.


Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jonsen A, Urowitz M J Rheumatol. 2019; 46(5):492-500.

PMID: 30647177 PMC: 7339909. DOI: 10.3899/jrheum.180713.


The role of osteopontin in kidney diseases.

Kaleta B Inflamm Res. 2018; 68(2):93-102.

PMID: 30456594 DOI: 10.1007/s00011-018-1200-5.


Myelopoiesis embraces its inner weakness.

Gerlic M, Croker B Nat Immunol. 2017; 18(9):953-954.

PMID: 28829446 PMC: 6289289. DOI: 10.1038/ni.3814.